SCHEMBL721575

SCHEMBL721575

N#Cc1nc(Br)ccc1OCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.45
CTSS P25774 1/20 0.42
SQOR Q9Y6N5 1/20 0.42
XDH P47989 3/20 0.41
MAPT P10636 3/20 0.41
HSD17B10 Q99714 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MEN1 O00255 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
USP8 P40818 1/20 0.40
MAPK1 P28482 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17544552 0.82 HTR1A (0.43) MAOBCTSSXDHMAPTHSD17B10
SCHEMBL3892947 0.82 MAPT (0.47) MAOBXDHMAPTHSD17B10L3MBTL1
SCHEMBL19331166 0.80 SQOR (0.41) MAOBCTSSSQORXDHSMN1; SMN2
SCHEMBL2950393 0.78 MAPT (0.49) MAOBCTSSSQORXDHMAPT
SCHEMBL2951718 0.78 MAPT (0.49) MAOBCTSSXDHMAPTHSD17B10
SCHEMBL2675108 0.76 LTA4H (0.58) MAOBMAPTL3MBTL1SMN1; SMN2HTT
SCHEMBL4214379 0.76 LTA4H (0.58) MAOBMAPTL3MBTL1ALDH1A1LMNA
SCHEMBL26460635 0.76 MAPT (0.43) MAOBMAPTL3MBTL1SMN1; SMN2HTT
SCHEMBL25679792 0.76 SMN1; SMN2 (0.56) MAPTL3MBTL1LMNAPOLBSMN1; SMN2
SCHEMBL2950688 0.76 XDH (0.40) MAOBCTSSXDHMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2980085-B1 PYRAZOLE DERIVATIVE TEIJIN PHARMA LTD (JP) 2018-03-14 EP disclosed
US-20170217980-A1 AMLEXANOX ANALOGS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2017-08-03 US disclosed
US-20170217980-A1 AMLEXANOX ANALOGS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2017-08-03 US disclosed
WO-2017132538-A1 AMLEXANOX ANALOGS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-08-03 WO disclosed
US-9617240-B2 Pyrazole derivative TEIJIN PHARMA LIMITED (JP) 2017-04-11 US disclosed
US-20160039784-A1 PYRAZOLE DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2016-02-11 US disclosed
EP-2980085-A1 PYRAZOLE DERIVATIVE Teijin Pharma Limited (JP) 2016-02-03 EP disclosed
CN-102015641-B Heterocyclic compound TAKEDA PHARMACEUTICAL 2014-01-01 CN disclosed
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 US disclosed
CN-100344632-C Fused furan compound TANABE SEIYAKU CO (JP) 2007-10-24 CN disclosed
US-20060094724-A1 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-05-04 US disclosed
CN-1723210-A Fused furan compound TANABE SEIYAKU CO (JP) 2006-01-18 CN disclosed
EP-1582521-A1 FUSED FURAN COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2005-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP MAOB 2146/4885CTSS 4471/4885SQOR 39/4885
US-20090156803-A1 Condensed furan compounds F2, F12, F11 MAOB 685/4885CTSS 1395/4885SQOR 116/4885
US-20160039784-A1 PYRAZOLE DERIVATIVE XDH, NLRP3, NLRP1 MAOB 2373/4885CTSS 1183/4885SQOR 151/4885
US-20060094724-A1 Fused furan compound F2, F12, F11 MAOB 658/4885CTSS 1947/4885SQOR 172/4885
US-20170217980-A1 AMLEXANOX ANALOGS GPR119, GLP1R, IRS1 MAOB 4548/4885CTSS 3502/4885SQOR 2397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.